---
input_text: 'The role of new medical treatments for the management of developmental
  and epileptic encephalopathies: Novel concepts and results. Developmental and epileptic
  encephalopathies (DEEs) are among the most challenging of all epilepsies to manage,
  given the exceedingly frequent and often severe seizure types, pharmacoresistance
  to conventional antiseizure medications, and numerous comorbidities. During the
  past decade, efforts have focused on development of new treatment options for DEEs,
  with several recently approved in the United States or Europe, including cannabidiol
  as an orphan drug in Dravet and Lennox-Gastaut syndromes and everolimus as a possible
  antiepileptogenic and precision drug for tuberous sclerosis complex, with its impact
  on the mammalian target of rapamycin pathway. Furthermore, fenfluramine, an old
  drug, was repurposed as a novel therapy in the treatment of Dravet syndrome. The
  evolution of new insights into pathophysiological processes of various DEEs provides
  possibilities to investigate novel and repurposed drugs and to place them into the
  context of their role in future management of these patients. The purpose of this
  review is to provide an overview of these new medical treatment options for the
  DEEs and to discuss the clinical implications of these results for improved treatment.'
raw_completion_output: |-
  primary_disease: Developmental and epileptic encephalopathies (DEEs)

  medical_actions: Development of new treatment options; Approval of cannabidiol as an orphan drug; Approval of everolimus; Repurposing of fenfluramine

  symptoms: Severe seizure types; Pharmacoresistance; Comorbidities

  chemicals: Cannabidiol; Everolimus; Fenfluramine

  action_annotation_relationships: Development of new treatment options PREVENTS Severe seizure types IN Developmental and epileptic encephalopathies (DEEs); Approval of cannabidiol (with Cannabidiol) TREATS Severe seizure types IN Developmental and epileptic encephalopathies (DEEs); Approval of everolimus (with Everolimus) TREATS Pharmacoresistance IN Developmental and epileptic encephalopathies (DEEs); Repurposing of fenfluramine (with Fenfluramine) TREATS Severe seizure types IN Developmental and epileptic encephalopathies (DEEs)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Repurposing of fenfluramine (with Fenfluramine) TREATS Severe seizure types IN Developmental and epileptic encephalopathies (DEEs)

  ===

extracted_object:
  primary_disease: MONDO:0100062
  medical_actions:
    - Development of new treatment options
    - Approval of cannabidiol as an orphan drug
    - Approval of everolimus
    - Repurposing of fenfluramine
  symptoms:
    - Severe seizure types
    - Pharmacoresistance
    - Comorbidities
  chemicals:
    - CHEBI:69478
    - CHEBI:68478
    - CHEBI:5000
  action_annotation_relationships:
    - subject: Development of new treatment options
      predicate: PREVENTS
      object: Severe seizure types
      qualifier: MONDO:0100062
    - subject: Approval of cannabidiol
      predicate: TREATS
      object: seizure types
      qualifier: MONDO:0100062
      subject_qualifier: with Cannabidiol
      object_qualifier: Severe
      subject_extension: CHEBI:69478
      object_extension: Severe
    - subject: Approval of everolimus
      predicate: TREATS
      object: Pharmacoresistance
      qualifier: MONDO:0100062
      subject_qualifier: with Everolimus
      subject_extension: CHEBI:68478
    - subject: Repurposing of fenfluramine
      predicate: TREATS
      object: Severe seizure types
      qualifier: MONDO:0100062
      subject_qualifier: with Fenfluramine
      object_qualifier: Severe
      subject_extension: CHEBI:5000
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
  - id: MAXO:0000943
    label: deep brain stimulation (DBS)
  - id: MAXO:0000940
    label: responsive neurostimulation (RNS)
  - id: MONDO:0005071
    label: Neurological disorders
  - id: CHEBI:133053
    label: 7-OH-CBD
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: HP:0001873
    label: thrombocytopenia
  - id: CHEBI:8107
    label: Phenytoin
  - id: HP:0012758
    label: Neurodevelopmental delays
  - id: HP:0011951
    label: Aspiration pneumonia
  - id: CHEBI:71013
    label: Perampanel
  - id: CHEBI:63004
    label: Sodium bromide
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0000718
    label: Aggression
  - id: HP:0031475
    label: nonconvulsive status epilepticus
  - id: HP:0001609
    label: hoarseness
  - id: HP:0000752
    label: hyperactivity
  - id: HP:0002446
    label: astrogliosis
  - id: CHEBI:9948
    label: verapamil
  - id: CHEBI:52140
    label: clemizole
  - id: CHEBI:3387
    label: Carbamazepine
  - id: CHEBI:40594
    label: AEDs
  - id: CHEBI:68478
    label: Everolimus
